Nastasic/E+ via Getty Images Introduction & Investment Thesis I last wrote about Hims & Hers Health (NYSE:HIMS) in May, where I initiated a "strong buy" rating based on my thesis that the stock should see significant upside as it focuses on growing its personalized solutions in existing and new specialties, with a goal of reaching $100M+ in revenue for each of its new specialties by 2025. Since then, the stock climbed over 100% to a peak price of $25 in June; however, it has since come back down to its curr ...

SAN DIEGO, Aug. 20, 2024 /PRNewswire/ -- As the popularity of GLP-1 receptor agonists continues to surge in the treatment of obesity and type 2 diabetes, Evofem Biosciences, Inc. (OTCQB: EVFM) is raising awareness of the potential impact these medications may have on the effectiveness of oral contraceptives. With an increasing number of women turning to GLP-1 medications for weight management and glycemic control, the need for reliable non-oral contraceptive options has never been more acute. GLP-1 receptor ...

● . ● | --- | --- | |---------------------------------------------------|-------| | | | | Defence Investigates the Application of the Accum | | | Hydrogel Technology to Deliver GLP-1 in Order to | | | Increase the Treatment Efficacy of Diabetes and | | August 19, 2024 9:27 AM EDT | Source: Defence Therapeutics Inc. Vancouver, British Columbia--(Newsfile Corp. - August 19, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company ...

Should Novo Nordisk and Eli Lilly investors be worried about Roche? Novo Nordisk (NVO -1.58%) and Eli Lilly (LLY -1.01%) are the top two companies in the weight loss market right now. They are both raking in billions in revenue from their glucagon-like peptide-1 (GLP-1) drugs. But given how lucrative the market is -- one estimate says it will be worth $100 billion by 2030 -- you can be sure that there will be a lot of competition. In fact, several small, up-and-coming healthcare companies are developing GLP ...

Mounjaro and Zepbound are likely to be Eli Lilly's top two products in the very near future. For a top drugmaker like Eli Lilly (LLY -1.01%), developing new drugs is key to ensuring that its business continues to grow. Patents don't last forever, so continuing to innovate is the only surefire way to be successful and remain a top company in the healthcare industry. In the past couple of years, the company has obtained approvals for multiple new products, including Mounjaro for diabetes, Zepbound for weight ...

TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. ("DiagnaMed" or the "Company") (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI, is offering its novel BRAIN AGE® Brain Health AI Platform ("BRAIN AGE®") as a clinical tool for investigating the impact of weight loss drugs, such as Semaglutide, on brain function. In a recently published study, Semaglutide, a GLP-1 receptor agonist that has been approved by the FDA and is currently marketed in vari ...

Dallas, Texas, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the areas of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, proudly announces the successful migration to its newly developed DEA-approved telemedicine operating system. This milestone marks a significant advancement in MangoRx's capabilities, reinf ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-32593 Global Partners LP (Exact name of registrant as specified in its charter) Delaware 74-3140887 (State or oth ...

Global Partners LP Common Units (NYSE:GLP) Q2 2024 Results Conference Call August 7, 2024 10:00 AM ET Company Participants Sean Geary - CLO & Secretary Eric Slifka - President & CEO Gregory Hanson - CFO Mark Romaine - COO Conference Call Participants Selman Akyol - Stifel Operator Good day, everyone, and welcome to the Global Partners Second Quarter 2024 Financial Results Conference Call. Today's call is being recorded. [Operator Instructions]. With us from Global Partners are President and Chief Executive ...

aprott/iStock via Getty Images Introduction Hims & Hers (NYSE:HIMS) — the viral telehealth platform that aims to help the world feel great through the power of better health — just reported Q2 earnings that obliterated all expectations. Throughout 2024, the stock has rallied as much as 200%, largely driven by the company's tremendous growth and relentless execution. However, much of the rally was driven by the rising popularity and subsequent shortages of GLP-1 drugs — having recently launched its Weight Lo ...